No price history available.
Key financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | TWDm | 3 | 38 | 54 | 94 | 338 | 379 | N/A | N/A |
| Operating profit | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net profit | TWDm | -54 | -54 | 136 | -42 | 30 | 107 | N/A | N/A |
| EPS reported | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating cashflow per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Capex per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Free cash flow | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value equity | TWDm | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Book value per share | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Number of shares | m | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| DPS (TTM paid) | TWD | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Financial summary
Financials in TWD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/B LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/S LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| P/FCF LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/EBITDA LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EV/Sales LTM | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Earnings Yield LTM | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Quality | |||||||||
| ROE | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| ROIC | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross margin | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Sales | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Growth and momentum | |||||||||
| EPS Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Sales Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Income Growth YoY | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Operating Profit Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend and capital structure | |||||||||
| Dividend Yield | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Dividend Growth | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Payout Ratio | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| FCF/Debt | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net Debt/EBITDA | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| EBIT/Net interest | x | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/market cap | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Net debt/Equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
| Gross debt/equity | % | Locked | Locked | Locked | Locked | Locked | Locked | Locked | Locked |
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
Ever Fortune.AI Co., Ltd. specializes in delivering cloud-based artificial intelligence solutions. Their product portfolio features a bone age evaluation system, which assists clinicians in determining a child's skeletal age and predicting their ultimate adult height. They also offer a sophisticated breast ultrasound tumor categorization system, designed to empower medical practitioners in tumor diagnosis and facilitate non-invasive screening to guide breast puncture and biopsy decisions concerning tumor malignancy. Additionally, the company provides a computed tomography-based system for assessing liver cancer metastatic risk, thereby enhancing radiologists' operational efficiency and evaluating the potential for metastasis. Their suite of tools further includes a liver fibrosis assessment system designed to measure liver scarring, and an atrial fibrillation detection system that interprets electrocardiogram signals to evaluate the heart's condition. Headquartered in Taichung City, Taiwan, Ever Fortune.AI Co., Ltd. operates as a subsidiary of An Ji Biomedical Corporation.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Ever Fortune.AI Co., Ltd. (6841.TWO)
No price history available.
Based on consensus from external analysts. Not Kvantra's opinion.
Ever Fortune.AI Co., Ltd. specializes in delivering cloud-based artificial intelligence solutions. Their product portfolio features a bone age evaluation system, which assists clinicians in determining a child's skeletal age and predicting their ultimate adult height. They also offer a sophisticated breast ultrasound tumor categorization system, designed to empower medical practitioners in tumor diagnosis and facilitate non-invasive screening to guide breast puncture and biopsy decisions concerning tumor malignancy. Additionally, the company provides a computed tomography-based system for assessing liver cancer metastatic risk, thereby enhancing radiologists' operational efficiency and evaluating the potential for metastasis. Their suite of tools further includes a liver fibrosis assessment system designed to measure liver scarring, and an atrial fibrillation detection system that interprets electrocardiogram signals to evaluate the heart's condition. Headquartered in Taichung City, Taiwan, Ever Fortune.AI Co., Ltd. operates as a subsidiary of An Ji Biomedical Corporation.